<DOC>
	<DOC>NCT02063308</DOC>
	<brief_summary>By doing this study, researchers hope to learn how much oxaloacetate (OAA) ends up in the blood after OAA capsules are swallowed, and to assess whether persons with Alzheimer's disease who take OAA for one month have any side-effects.</brief_summary>
	<brief_title>Oxaloacetate Pharmacokinetics and Safety</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Meet criteria for Mild or Moderate AD Have a study partner Speak English as primary language. Absence of a study partner Report a potentially confounding, serious medical risk such as type 1 diabetes, cancer, or a recent cardiac event (i.e. heart attack, angioplasty, etc.)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Oxaloacetate</keyword>
	<keyword>OAA</keyword>
	<keyword>AD</keyword>
	<keyword>Alzheimer's Disease</keyword>
</DOC>